| Autor: |
Buszka K; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.; Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland., Ntzifa A; Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece., Owecka B; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland., Kamińska P; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.; Doctoral School, Poznan University of Medical Sciences, 60-812 Poznan, Poland., Kolecka-Bednarczyk A; Department of Immunology, Chair of Pathomorphology and Clinical Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland., Zabel M; Division of Anatomy and Histology, University of Zielona Góra, 65-046 Zielona Góra, Poland., Nowicki M; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland., Lianidou E; Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece., Budna-Tukan J; Department of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland. |
| Abstrakt: |
The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in patients with certain gene alterations, including EGFR , ALK , ROS1 , BRAF , and MET genes. Molecular targeted therapy based on TKIs has improved clinical outcomes in a large number of NSCLC patients with advanced disease, enabling significantly longer progression-free survival (PFS). Liquid biopsy is an increasingly popular diagnostic tool for treating TKI-based NSCLC. The studies presented in this article show that detection and analysis based on liquid biopsy elements such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and/or tumor-educated platelets (TEPs) can contribute to the appropriate selection and monitoring of targeted therapy in NSCLC patients as complementary to invasive tissue biopsy. The detection of these elements, combined with their molecular analysis (using, e.g., digital PCR (dPCR), next generation sequencing (NGS), shallow whole genome sequencing (sWGS)), enables the detection of mutations, which are required for the TKI treatment. Despite such promising results obtained by many research teams, it is still necessary to carry out prospective studies on a larger group of patients in order to validate these methods before their application in clinical practice. |
